At AAN 2026, Argenx announced positive results from the Phase III, double-blind, placebo-controlled, ADAPT SERON study of Vyvgart.

The post AAN 2026: new Vyvgart data show disease control in seronegative gMG appeared first on Clinical Trials Arena.